235106-53-3

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridin-6-amine (9CI) serves as a key intermediate in the synthesis of various pharmaceutical compounds for its unique structural properties. It is utilized in the development of new drugs targeting a spectrum of diseases and conditions.
Used in Cancer Treatment:
In the field of oncology, Imidazo[1,2-a]pyridin-6-amine (9CI) is employed as a potential therapeutic agent for the treatment of various types of cancer. Its incorporation into drug molecules can enhance their efficacy in targeting and combating cancer cells.
Used in Neurological Disorders Treatment:
Imidazo[1,2-a]pyridin-6-amine (9CI) also finds application in the treatment of neurological disorders. Its unique structure allows for the development of drugs that can effectively address the complex nature of these conditions, offering new avenues for therapeutic intervention.
Used in Drug Discovery and Development:
As a significant compound in drug discovery and development, Imidazo[1,2-a]pyridin-6-amine (9CI) is used for the exploration of novel pharmacological properties and the creation of innovative therapeutic agents. Its potential in various disease areas makes it a valuable asset in the advancement of medical treatments.

InChI:InChI=1/C7H7N3/c8-6-1-2-7-9-3-4-10(7)5-6/h1-5H,8H2

Upstream product

• 4214-76-0 5-nitro-pyridin-2-ylamine 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 25045-82-3 6-nitroimidazo[1,2-a]pyridine 

Downstream Products

• 1257857-59-2 phenyl imidazo[1,2-a]pyridin-6-ylcarbamate 
• 421595-88-2 C₂₅H₂₀N₃P 
• 421595-97-3 7-ethyl-8-methylimidazo[1,2-a][1,5]naphthyridine 

Relevant academic research and scientific papers

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES

The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, formula (I): wherein: R1 is C3-8-cycloalkyl; X is O, NR7 or C3-6-heterocycloalkyl; R2 is aryl, heteroaryl, fused or unfused aryl-C3-6-heterocycloalkyl or fused or unfused heteroaryl-C3-6-heterocycIoalkyl, each of which is optionally substituted by one or more substitutents selected from aryl, heteroaryl, C1-6-alkyl, C3-7-cycloalkyl and a group A, wherein said C1-6-alkyl group is optionally substituted by one or more substituents selected from aryl, heteroaryl, R10 and a group A, said heteroaryl group is optionally substituted by one or more R10 groups; and wherein said C3-6-heterocycloalkyl group optionally contains one or more groups selected from oxygen, sulfur, nitrogen and CO; R3 is C1-6-alkyl optionally substituted by one or more substituents selected from aryl, heteroaryl, -NR4R5, -OR6, -NR7(CO)R6, -NR7(CO)NR4R5, -NR7SO2R6, -NR7COOR7, -CONR4R5, C3-6-heterocycloalkyl and formula (a, b, c): wherein R4-7 and A are as defined in the claims. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of one or more kinases.

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.